6505--Bulk Order Impavido (miltefosine)
ID: 36C26025P0684Type: Special Notice
AwardedMay 1, 2025
$299.7K$299,700
AwardeePROFOUNDA INC ORLANDO 32824 FLK
Award #:36C26025P0684
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OF260-NETWORK CONTRACT OFFICE 20 (36C260)VANCOUVER, WA, 98661, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/a67b4d302e874c6885572992645db2e1/view
Timeline
    Description

    The Department of Veterans Affairs is seeking to procure a bulk order of Impavido (miltefosine) through a sole source contract with Profounda, Inc., which holds exclusive licensing rights for this medication in the U.S. This procurement is essential for treating a Veteran suffering from Disseminated Cutaneous Acanthamboeba, as no alternative treatments are available. The contract period is set from May 1, 2025, to October 30, 2025, with an estimated cost of $299,700, and interested parties must respond by April 23, 2025, at 1:00 PM Pacific Time. For further inquiries, potential suppliers can contact Jose E Ronstadt at jose.ronstadt@va.gov or by phone at 360-852-9885.

    Point(s) of Contact
    Jose E Ronstadtjose.ronstadt@va.gov
    (360) 852-9885
    jose.ronstadt@va.gov
    Files
    Title
    Posted
    36C26025P0684_2.docx
    This Special Notice from the Network Contracting Office 20 announces an intent to sole source a bulk order of Impavido (miltefosine). The document outlines essential information regarding the solicitation number (36C26025P0684), response deadline (April 23, 2025, at 1:00 PM Pacific Time), and the agency’s contact details, including the point of contact, Jose E Ronstadt. The notice specifies that no Recovery Act funds will be used and provides relevant product service (6505) and NAICS codes (325412). It indicates that the full details can be found in an attached document (P03 36C260-25-AP-2676). For additional information, the contracting office is accessible via the System for Award Management (SAM) website. This notice is critical for informing potential suppliers about the procurement intentions of the government regarding the specific pharmaceutical product.
    P03 36C260-25-AP-2676.pdf
    The document outlines a Request for Sole Source Justification for the acquisition of IMPAVIDO, a medication necessary for a Veteran suffering from Disseminated Cutaneous Acanthamboeba, through Profounda, Inc. The contract period is set from May 1, 2025, to October 30, 2025, with an estimated cost of $299,700. The justification cites that only Profounda, Inc. can supply IMPAVIDO as they hold exclusive licensing rights in the U.S., and no alternative treatments exist. Efforts to identify capable vendors revealed that none could provide the required drug, affirming the sole-source approach. The anticipated cost is deemed fair and reasonable, aligning with a previous purchase order for the same item. The document concludes with required certifications from both the Program Analyst and the Contracting Officer, affirming the necessity and accuracy of the justification under federal procurement guidelines, thereby validating the decision to proceed with this sole source acquisition. This supports the Department of Veterans Affairs’ commitment to providing specific healthcare needs for Veterans effectively and expediently.
    Similar Opportunities
    6505--Ustekinumab Pens/Syringes or Biosimilar
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Ustekinumab Pens/Syringes or Biosimilars, aimed at supplying various federal health entities including the Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract will be awarded for an initial period of one year, with the possibility of four additional one-year option periods, ensuring a consistent supply of these critical pharmaceutical products through the VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must provide drugs with unique National Drug Code (NDC) numbers and ensure that any biosimilar products meet FDA licensing requirements, as outlined in the FDA Purple Book. The solicitation is expected to be released around January 12, 2026, with a tentative closing date of January 27, 2026; interested parties should direct inquiries to Chris Carthron at Christopher.Carthron@va.gov or (708) 786-4980.
    6505--Biologics by McKesson Specialty Pharmacy (Lenalidomide) (VA-26-00016920)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking qualified suppliers to provide Lenalidomide, a pharmaceutical product, for the Oscar G. Johnson VA Medical Center located in Iron Mountain, MI. This procurement will be conducted through a Brand Name or Equal Request for Quotation (RFQ) under firm-fixed price terms, following FAR Part 13 Simplified Acquisition Procedures. Lenalidomide is crucial for treating certain conditions, making this procurement significant for patient care within the VA system. Interested offerors must submit an itemized quote along with sufficient technical documentation via email to arneil.genus@va.gov by 3 p.m. Central on December 1, 2025, as telephone inquiries will not be accepted.
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    6505--LEVOFLOXICIN 750MG / DEXTROSE 5% 150ML, IVPB (VA-26-00008212)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking small business vendors to supply LEVOFLOXICIN 750MG / DEXTROSE 5% 150ML, IVPB, as part of solicitation number 36C77026Q0005. This procurement involves delivering a total of 1,460 boxes of the pharmaceutical product to the VA CMOP facility in Hines, Illinois, with a base period and four option years, each requiring delivery by January 5th of the respective year. The goods are critical for patient care within the VA healthcare system, emphasizing the importance of timely and compliant delivery. Interested vendors must submit their proposals, including a signed SF 1449, pricing schedule, and other required documentation, by December 16, 2025, at 3 PM Central Time, and can direct inquiries to Contract Specialist Jennifer Coleman at Jennifer.Coleman4@va.gov.
    6505--LANSOPRAZOLE
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking to procure Lansoprazole, a pharmaceutical product, for the Tucson Consolidated Mail Outpatient Pharmacy (CMOP). This procurement is justified as a sole source requirement, indicating that Lansoprazole is essential for the pharmacy's operations and patient care. The drug falls under the category of drugs and biologicals, highlighting its critical role in treating various medical conditions. Interested vendors can reach out to Contract Specialist Brigitte Kidder at Brigitte.Kidder@va.gov or by phone at 913-946-0150 for further details regarding this opportunity.
    6505--Zonisamide Capsules
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking qualified suppliers for a Firm Fixed Price, Indefinite-Delivery Requirements contract for Zonisamide Capsules in 25mg, 50mg, and 100mg dosages. Offerors are required to provide pricing for a base year and four option years, submit a 0.5% Cost Recovery Fee, and comply with stringent packaging and barcoding standards, including adherence to the Drug Supply Chain Security Act (DSCSA) and National Drug Code (NDC) requirements. These pharmaceutical products are crucial for the healthcare services provided to veterans and military personnel through the VA and DoD Pharmaceutical Prime Vendor Programs. Interested parties should contact Contract Specialist Christopher Carthron at Christopher.Carthron@va.gov for further details, and ensure they meet all compliance and registration requirements, including current SAM registration.
    COLESTIPOL HCL 1GM TAB and DESONIDE 0.05% CREAM - 762 TUCSON
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is conducting a Sources Sought Notice to identify potential qualified domestic sources for the procurement of COLESTIPOL HCL 1GM TAB and DESONIDE 0.05% CREAM through its National CMOP Office. This announcement serves as a market research tool rather than a solicitation, aiming to gather information on vendors' capabilities to meet the requirements outlined in the Statement of Requirements. The products sought are critical for pharmaceutical preparation and will support the healthcare needs of veterans. Interested vendors must submit their responses, including company details and capability statements, via email to Jennifer Coleman at Jennifer.Coleman4@va.gov by December 19, 2025, at 3:00 PM CDT. This notice does not obligate the VA to issue a solicitation.
    6505--Supply, RADIOPHARMACEUTICALS DATSCAN - NBD 1/1 Indianapolis VAMC
    Veterans Affairs, Department Of
    The Department of Veterans Affairs, specifically the Indianapolis Veterans Affairs Medical Center (VAMC), intends to issue a sole source contract to Medi-Physics, Inc. for the procurement of 20 units of DaTscan Ioflupane, a radiopharmaceutical essential for conducting diagnostic tests. This acquisition is based on the authority of FAR Part 6.302-1, which allows for negotiation with only one responsible source, as Medi-Physics, Inc. is the sole vendor on the Federal Supply Schedule (FSS) contract for this product. The contract is anticipated to be a firm-fixed price agreement with no option years, and responses to this notice must be submitted by 12:00 pm on December 17, 2025, to the primary contact, Rachel MacRae, at rachel.macrae@va.gov or by phone at 734-222-4326.
    6505--Pylarify 2026 (VA-26-00025867) RFI
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is seeking qualified sources to provide F18 PSMA Pylarify, a radiopharmaceutical used for positron emission tomography (PET) imaging of prostate cancer, to the Baltimore VA Medical Center. The procurement aims to identify contractors capable of manufacturing, preparing, and transporting this specialized radiopharmaceutical in compliance with stringent regulatory standards, including USNRC, DOT, and FDA guidelines. Pylarify is critical for diagnosing prostate cancer by identifying PSMA-positive lesions, thus playing a vital role in patient care. Interested parties must submit their responses, including company information and qualifications, by December 17, 2025, at 10:00 AM EST, to Contract Specialist Michael Jones at michael.jones16@va.gov.
    6505--Notice of Intent to Award a Sole Source Procurement - Xofigo Radium-223 dichloride
    Veterans Affairs, Department Of
    The Department of Veterans Affairs, specifically the Network Contracting Office 17, intends to award a sole source, firm-fixed-price contract to Cardinal Health for the procurement of 660 units of XOFIGO® (Radium-223 dichloride). This procurement is based on a letter from Bayer Healthcare, which designates Cardinal Health as the sole distributor of XOFIGO® in the United States, highlighting the critical nature of this pharmaceutical in treating specific medical conditions. Interested parties may submit capability statements or proposals within seven days of the notice's publication, with the deadline set for December 19, 2025; otherwise, the contract will be awarded to Cardinal Health without further notice. For inquiries, contact Vance Farrell at vance.farrell@va.gov or call 210-694-6379.